Cargando…

New Criteria for Lupus

PURPOSE OF THE REVIEW: Classification criteria define the patient population for clinical trials and translational studies, but also influence current understanding of the disease. This review attempts to delineate the development from the American College of Rheumatology (ACR) 1982 to the European...

Descripción completa

Detalles Bibliográficos
Autores principales:	Aringer, Martin, Leuchten, Nicolai, Johnson, Sindhu R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2020
Materias:	Systemic Lupus Erythematosus (G Tsokos, Section Editor)
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7220972/ https://www.ncbi.nlm.nih.gov/pubmed/32405775 http://dx.doi.org/10.1007/s11926-020-00896-6

Ejemplares similares

New Attempts to Define and Clarify Lupus
por: Alarcón-Riquelme, Marta E.
Publicado: (2019)

Cell Senescence in Lupus
por: Gao, Lin, et al.
Publicado: (2019)

Systemic Lupus Erythematosus in Children and Young People
por: Charras, A., et al.
Publicado: (2021)

SARS-CoV-2 and Systemic Lupus Erythematosus
por: Thanou, Aikaterini, et al.
Publicado: (2021)

The Representation of Gender and Race/Ethnic Groups in Randomized Clinical Trials of Individuals with Systemic Lupus Erythematosus
por: Falasinnu, Titilola, et al.
Publicado: (2018)

Epigenetics in SLE
por: Hedrich, Christian Michael
Publicado: (2017)

The Use of COVID-19 Vaccines in Patients with SLE
por: Tang, Wei, et al.
Publicado: (2021)

A Review of Complement Activation in SLE
por: Weinstein, Arthur, et al.
Publicado: (2021)

Belimumab in systemic lupus erythematosus
por: Vilas-Boas, Andreia, et al.
Publicado: (2015)

Sensitivity to Change and Minimal Important Differences of the LupusQoL in Patients With Systemic Lupus Erythematosus
por: McElhone, Kathleen, et al.
Publicado: (2016)

Weaning of maintenance immunosuppressive therapy in lupus nephritis (WIN-Lupus): results of a multicentre randomised controlled trial
por: Jourde-Chiche, Noemie, et al.
Publicado: (2022)

Lupus low disease activity state attainment in the phase 3 TULIP trials of anifrolumab in active systemic lupus erythematosus
por: Morand, Eric F, et al.
Publicado: (2023)

Oxidative Stress, T Cell DNA Methylation, and Lupus
por: Li, YePeng, et al.
Publicado: (2014)

Dietary Omega Polyunsaturated Fatty Acid Intake and Patient‐Reported Outcomes in Systemic Lupus Erythematosus: The Michigan Lupus Epidemiology and Surveillance Program
por: Charoenwoodhipong, Prae, et al.
Publicado: (2020)

Complement Activation in Patients With Probable Systemic Lupus Erythematosus and Ability to Predict Progression to American College of Rheumatology–Classified Systemic Lupus Erythematosus
por: Ramsey‐Goldman, Rosalind, et al.
Publicado: (2019)

Impact of Belimumab on Organ Damage in Systemic Lupus Erythematosus
por: Urowitz, Murray B., et al.
Publicado: (2022)

Study of Flare Assessment in Systemic Lupus Erythematosus Based on Paper Patients
por: Isenberg, D., et al.
Publicado: (2017)

Lupus or not? SLE Risk Probability Index (SLERPI): a simple, clinician-friendly machine learning-based model to assist the diagnosis of systemic lupus erythematosus
por: Adamichou, Christina, et al.
Publicado: (2021)

Biological impact of iberdomide in patients with active systemic lupus erythematosus
por: Lipsky, Peter E, et al.
Publicado: (2022)

Choroid Plexus–Infiltrating T Cells as Drivers of Murine Neuropsychiatric Lupus
por: Moore, Erica, et al.
Publicado: (2022)

What Does It Mean to Be a British Isles Lupus Assessment Group–Based Composite Lupus Assessment Responder? Post Hoc Analysis of Two Phase III Trials
por: Furie, Richard, et al.
Publicado: (2021)

Psychosis in Systemic Lupus Erythematosus: Results From an International Inception Cohort Study
por: Hanly, John G., et al.
Publicado: (2019)

Long‐Term Clinical Outcomes in a Cohort of Adults With Childhood‐Onset Systemic Lupus Erythematosus
por: Groot, N., et al.
Publicado: (2019)

Brief Report: A Randomized, Double‐Blind, Parallel‐Group, Placebo‐Controlled, Multiple‐Dose Study to Evaluate AMG 557 in Patients With Systemic Lupus Erythematosus and Active Lupus Arthritis
por: Cheng, Laurence E., et al.
Publicado: (2018)

Association of Systemic Lupus Erythematosus With Decreased Immunosuppressive Potential of the IgG Glycome
por: Vučković, Frano, et al.
Publicado: (2015)

Association of Blood Concentrations of Complement Split Product iC3b and Serum C3 With Systemic Lupus Erythematosus Disease Activity
por: Kim, Alfred H. J., et al.
Publicado: (2019)

Phase II Randomized Trial of Rituximab Plus Cyclophosphamide Followed by Belimumab for the Treatment of Lupus Nephritis
por: Atisha‐Fregoso, Yemil, et al.
Publicado: (2020)

Mechanism of action of baricitinib and identification of biomarkers and key immune pathways in patients with active systemic lupus erythematosus
por: Dörner, Thomas, et al.
Publicado: (2022)

Transcriptome reprogramming and myeloid skewing in haematopoietic stem and progenitor cells in systemic lupus erythematosus
por: Grigoriou, Maria, et al.
Publicado: (2020)

Distinct roles for complement in glomerulonephritis and atherosclerosis revealed in mice with a combination of lupus and hyperlipidemia
por: Lewis, Myles J, et al.
Publicado: (2012)

Lupus nephritis is linked to disease-activity associated expansions and immunity to a gut commensal
por: Azzouz, Doua, et al.
Publicado: (2019)

Molecular pathways in patients with systemic lupus erythematosus revealed by gene-centred DNA sequencing
por: Sandling, Johanna K, et al.
Publicado: (2021)

3D genome alterations in T cells associated with disease activity of systemic lupus erythematosus
por: Zhao, Ming, et al.
Publicado: (2023)

Global epidemiology of systemic lupus erythematosus: a comprehensive systematic analysis and modelling study
por: Tian, Jingru, et al.
Publicado: (2023)

Longitudinal gut microbiome analyses and blooms of pathogenic strains during lupus disease flares
por: Azzouz, Doua F, et al.
Publicado: (2023)

Predictors of Unsuccessful Hydroxychloroquine Tapering and Discontinuation: Can We Personalize Decision‐Making in Systemic Lupus Erythematosus Treatment?
por: Almeida‐Brasil, Celline C., et al.
Publicado: (2022)

Peroxisome proliferator activated receptor-γ agonist pioglitazone improves vascular and metabolic dysfunction in systemic lupus erythematosus
por: Hasni, Sarfaraz, et al.
Publicado: (2022)

Efficacy and Safety of Subcutaneous Belimumab in Anti–Double‐Stranded DNA–Positive, Hypocomplementemic Patients With Systemic Lupus Erythematosus
por: Doria, A., et al.
Publicado: (2018)

Lupus-associated atypical memory B cells are mTORC1-hyperactivated and functionally dysregulated
por: Wu, Chunmei, et al.
Publicado: (2019)

Altered cognitive function in systemic lupus erythematosus and associations with inflammation and functional and structural brain changes
por: Barraclough, Michelle, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_tk4ggcd6ln203b61g02s31mqcp